Wednesday, July 8, 2026

biotech · Advanced Solid Tumors · Tumor, Solid · EIKN

Eikon Therapeutics

Eikon Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

230 Harriet Tubman Way, Millbrae, CA 94030, US HQ
2019 Founded
404 Employees
Public company Type
EIKN · NYSE Ticker
Company details
Status
Public
HQ
230 Harriet Tubman Way, Millbrae, CA 94030, US
Founded
2019
Employees
404
Programs
15
Drugs
13
Patents
4
Intelligence · Clinical Programs

Eikon Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Eikon Therapeutics.

Eikon Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. EIK1001

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial
  2. EIK1001

    Eikon Therapeutics

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial
  3. EIK1001-006

    Eikon Therapeutics

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Eikon Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.